Acquirer Profile
Lilly Acquisitions & Deals (2026)
biotechnology · Pharmaceuticals · Biotechnology
Deals tracked
14
Combined value
$10.4B
Primary sector
biotechnology
Active
2026
FireStrike tracks every Lilly acquisition, merger, and strategic investment in real time. This page covers 14 Lilly deals totaling $10.4B in disclosed deal value, spanning biotechnology, Pharmaceuticals, Biotechnology. Data covers 2026.
Lilly Acquisitions — Full List
| Target company | Announced | Source |
|---|---|---|
Centessa Pharmaceuticals Pharmaceuticals | Apr 2026 | |
Orna Therapeutics Biotechnology | Feb 2026 | |
Ajax Therapeutics Pharmaceuticals | Apr 2026 | |
Kelonia Therapeutics biotechnology | Apr 2026 | |
Repertoire Immune Medicines Pharmaceuticals | Jan 2026 | |
Ventyx Biosciences Pharmaceuticals | Jan 2026 | |
Ventyx Biosciences Inc. biopharmaceutical | Jan 2026 | |
Seamless Therapeutics biotechnology | Feb 2026 | |
InduPro biotech | Jan 2026 | |
CrossBridge Bio Biotechnology | Apr 2026 | |
CrossBridge Bio, Inc. biotechnology | Apr 2026 | |
Veradermics biopharma | Feb 2026 | |
Adverum Biotechnologies Biotechnology | Feb 2026 | |
Aktis Oncology Pharmaceuticals | Jan 2026 |
Lilly Acquisitions — FAQ
How many acquisitions has Lilly made?
Lilly has made 14 acquisitions and deals tracked on FireStrike, totaling $10.4B in combined deal value.
What sectors does Lilly acquire in?
Lilly primarily acquires in biotechnology, Pharmaceuticals, Biotechnology.
What is Lilly's most recent acquisition?
Lilly's most recent tracked acquisition is Centessa Pharmaceuticals for $7.8B, announced Apr 2026.
Get every Lilly deal in your inbox
FireStrike tracks M&A, IPOs, and fundraises daily — free.
Start tracking free →